Document is current
Any future updates will be listed below
-
Authors
Freeman, Jincong Q.
Shubeck, Sarah P.
Chen, Nan
Yarlagadda, Sudha R.
Nanda, Rita
Huo, Dezheng
Howard, Frederick M.
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-23-071)
National Institute on Aging (T32AG000243)
Susan G. Komen (TREND21675016)
U.S. Department of Defense (BC211095)
U.S. Department of Defense (BC211095P1)
National Cancer Institute (K08CA283261)
National Cancer Institute (P20CA233307)
Agency for Healthcare Research and Quality (R03HS025806)
- License Information
-
More Information
Article History
Received: 3 June 2024
Accepted: 24 August 2024
First Online: 9 September 2024
Disclosures
: JQF, SPS, SRY, and DH have no financial or non-financial competing interests to disclose. FMH has disclosed consulting with Novartis. RN has disclosed advisory board involvement with and research funding from Arvinas, AstraZeneca, BeyondSpring, Celgene, FujiFilm, Genentech/Roche, Gilead, Infinity, iTeos, Merck, OBI Pharma, OncoSec, Pfizer, Relay Therapeutics, SeaGen, Sun Pharma, and Taiho. NC has disclosed consulting with Seagen and Guardant Health and research funding from Eli Lilly.
: The National Cancer Database contains de-identified patient-level data that do not identify patients, hospitals, or health care providers, as agreed to in the Business Associate Agreement that each Commission on Cancer-accredited program has signed with the American College of Surgeons. Therefore, study-specific ethics approval was waived by the University of Chicago Institutional Review Board.
